JP2005518414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005518414A5 JP2005518414A5 JP2003562087A JP2003562087A JP2005518414A5 JP 2005518414 A5 JP2005518414 A5 JP 2005518414A5 JP 2003562087 A JP2003562087 A JP 2003562087A JP 2003562087 A JP2003562087 A JP 2003562087A JP 2005518414 A5 JP2005518414 A5 JP 2005518414A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- alkoxy
- aryl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000001589 carboacyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- 125000003435 aroyl group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 4
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- -1 nitro, hydroxy Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims 2
- AQJQWVUKYSGAFK-UHFFFAOYSA-N 3-methyl-7-(4-methyl-3-phenylphenyl)sulfonyl-1,2,4,5-tetrahydro-3-benzazepine Chemical compound C1=C2CCN(C)CCC2=CC=C1S(=O)(=O)C(C=1)=CC=C(C)C=1C1=CC=CC=C1 AQJQWVUKYSGAFK-UHFFFAOYSA-N 0.000 claims 1
- WQSGSEVNXMQZMW-UHFFFAOYSA-N 4-[3-(2,3,4,5-tetrahydro-1h-3-benzazepin-7-ylsulfonyl)phenyl]benzonitrile Chemical compound C=1C=C2CCNCCC2=CC=1S(=O)(=O)C(C=1)=CC=CC=1C1=CC=C(C#N)C=C1 WQSGSEVNXMQZMW-UHFFFAOYSA-N 0.000 claims 1
- DUAPBDVLFOZASB-UHFFFAOYSA-N 7-(4-methyl-3-phenylphenyl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound CC1=CC=C(S(=O)(=O)C=2C=C3CCNCCC3=CC=2)C=C1C1=CC=CC=C1 DUAPBDVLFOZASB-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0130702A GB0130702D0 (en) | 2001-12-21 | 2001-12-21 | Novel compounds |
| GB0212398A GB0212398D0 (en) | 2002-05-29 | 2002-05-29 | Compounds |
| PCT/EP2002/014824 WO2003062205A1 (en) | 2001-12-21 | 2002-12-20 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005518414A JP2005518414A (ja) | 2005-06-23 |
| JP2005518414A5 true JP2005518414A5 (enExample) | 2006-01-12 |
Family
ID=27614779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003562087A Pending JP2005518414A (ja) | 2001-12-21 | 2002-12-20 | ドーパミン受容体のモジュレーターとしての７−スルホニル−３−ベンゾアゼピン誘導体およびｃｎｓ障害の治療のためのその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20050176759A1 (enExample) |
| EP (1) | EP1456178A1 (enExample) |
| JP (1) | JP2005518414A (enExample) |
| WO (1) | WO2003062205A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04009318A (es) * | 2002-03-27 | 2005-01-25 | Glaxo Group Ltd | Derivados de quinolina y su uso como ligados 5-ht6. |
| TWI281914B (en) | 2002-05-29 | 2007-06-01 | Glaxo Group Ltd | Compounds |
| JP4198733B2 (ja) | 2003-07-22 | 2008-12-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 関連性障害の予防および処置に有用な、５−ｈｔ２ａセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体 |
| WO2005014578A1 (en) * | 2003-08-08 | 2005-02-17 | Glaxo Group Limited | Phenylsulfonyl compounds as antipsychotic agents |
| GB0319235D0 (en) * | 2003-08-15 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| GB0321475D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| WO2005042491A1 (en) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327737D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| GB0327738D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compound |
| GB0327741D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| MX2007007481A (es) * | 2004-12-21 | 2007-07-20 | Hoffmann La Roche | Derivados de tetralina e indano y usos de los mismos. |
| US20100173890A1 (en) * | 2005-07-05 | 2010-07-08 | Astrazeneca Ab | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| KR20090009275A (ko) * | 2006-05-31 | 2009-01-22 | 에프. 호프만-라 로슈 아게 | 모노아민 재흡수 억제제로서 벤즈아제핀 유도체 |
| WO2008113818A1 (en) * | 2007-03-21 | 2008-09-25 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| WO2009067621A1 (en) | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| JP5491421B2 (ja) | 2008-03-04 | 2014-05-14 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| KR20130112848A (ko) | 2010-06-02 | 2013-10-14 | 아레나 파마슈티칼스, 인크. | 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법 |
| SG188361A1 (en) | 2010-09-01 | 2013-04-30 | Arena Pharm Inc | Non-hygroscopic salts of 5-ht2c agonists |
| JP6272695B2 (ja) | 2010-09-01 | 2018-01-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 体重管理のために有用な５−ｈｔ２ｃアゴニストの改変放出剤形 |
| WO2012030938A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Salts of lorcaserin with optically active acids |
| CA2808890A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | Administration of lorcaserin to individuals with renal impairment |
| JP2015534563A (ja) | 2012-10-09 | 2015-12-03 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 体重管理の方法 |
| WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| HK1247555A1 (zh) | 2015-07-15 | 2018-09-28 | Axovant Sciences Gmbh | 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物 |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9612884D0 (en) * | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| PE20001088A1 (es) * | 1998-10-08 | 2000-12-02 | Smithkline Beecham Plc | Compuestos derivados de tetrahidrobenzazepina |
| AR022228A1 (es) * | 1999-01-12 | 2002-09-04 | Abbott Gmbh & Co Kg | Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion |
-
2002
- 2002-12-20 WO PCT/EP2002/014824 patent/WO2003062205A1/en not_active Ceased
- 2002-12-20 JP JP2003562087A patent/JP2005518414A/ja active Pending
- 2002-12-20 US US10/499,776 patent/US20050176759A1/en not_active Abandoned
- 2002-12-20 EP EP02796752A patent/EP1456178A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005518414A5 (enExample) | ||
| CN1087294C (zh) | 新化合物 | |
| JP2005526723A5 (enExample) | ||
| JP2005522452A5 (enExample) | ||
| RU2005136355A (ru) | Производные сульфонамида, их получение и применение в качестве лекарственных средств | |
| JP2006514011A5 (enExample) | ||
| JP2007505922A5 (enExample) | ||
| JP2005504039A5 (enExample) | ||
| JP2009541461A5 (enExample) | ||
| JP2007500168A5 (enExample) | ||
| HUP0300350A2 (hu) | Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
| JP2002523508A5 (enExample) | ||
| JP2005513016A5 (enExample) | ||
| JPWO2013105608A1 (ja) | Ｐ２ｘ４受容体拮抗剤 | |
| RU2006105777A (ru) | Индол-6-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 | |
| CN1535146A (zh) | 用作5－ht6和/或5－ht75－羟色胺受体的配体的5－卤代－色胺衍生物 | |
| JP2005527542A5 (enExample) | ||
| JP2015528821A5 (enExample) | ||
| WO1998029397A1 (en) | Fused pyrimidine compounds and medicinal use thereof | |
| HUP0300480A2 (hu) | 2-Acil-indol-származékok és tumorellenes szerként történő alkalmazásuk | |
| AU2016298962B2 (en) | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | |
| JP2007504229A5 (enExample) | ||
| RU2004122129A (ru) | Производные индолилалкиламина в качестве лтгандов 5-гидрокситриптамина-6 | |
| RU2006105782A (ru) | Производные 1-сульфонилиндола, их получение и их применение в качестве лигандов 5-нт-6 | |
| RU2006105779A (ru) | Индол-5-ильные сульфонамидные производные, их получение и их применение в качестве модуляторов 5-нт-6 |